Company intelligence / Profile preview
NanoRay Biotech
Taiwannanoray.com ↗
- Ownership
- Private
- Employees
- ~45
- Development stage
- Other
01
Overview
NanoRay’s lead oncology program, Auger Molecular Therapy (AMT), received IND approval from both the US FDA and Taiwan FDA in 2022. The first-in-human Phase 1 trial is scheduled to begin at Taipei Medical University Hospital. Their RevoluX hand diagnostic radiology system has been approved by the USFDA and TFDA for clinical use in bone age, bone density, and gout detection.
- Therapeutic areas
- RheumatologyEndocrinologyOncology
- Modalities
- DeviceSmall molecule (IUdR, as part of Auger Molecular Therapy)Radiotherapy-based therapy (Auger effect via monochromatic X-ray)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
BioDuro-Sundia – CRDMO partner supporting dosage form development, API production & clinical trial materials manufacturing for AMT program
Beyond the preview
Go deeper on NanoRay Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NanoRay Biotech.